# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Acadia's Phase 3 Compass Prader-Willi syndrome trial failed to meet endpoints, but the company projects $1 billion in sales...
-SEC Filing
https://x.com/ScorpionFund/status/1960731687903498571
Guggenheim analyst Debjit Chattopadhyay reiterates Soleno Therapeutics (NASDAQ:SLNO) with a Buy and maintains $106 price tar...
Wells Fargo analyst Derek Archila initiates coverage on Soleno Therapeutics (NASDAQ:SLNO) with a Overweight rating and annou...
https://x.com/scorpionfund/status/1957809005222330512?s=46&t=dtUiyC3dUs5yGRgT9qYHWg